1. Background {#sec0005}
=============

NAC is described as a mucolytic nutrient with anti-inflammatory, antioxidant and immunomodulating properties. NAC is reported to be used by naturopathic practitioners in some countries to assist in the management of some respiratory complaints. NAC has been found to be a glutathione (GSH) agonist with previous studies demonstrating that NAC administration increases GSH levels in red blood cells, granulocytes, and plasma of patients with acute respiratory distress syndrome or acute lung injury. Increasing GSH levels in the early phases of acute lung injury with NAC could reduce or limit the extent of epithelial and endothelial damage and improve the clinical course.

2. Search strategy {#sec0010}
==================

2.1. Research question {#sec0015}
----------------------

What are the effects of N-acetyl cysteine on acute respiratory viral infections (ARVI) and associated complications?

2.2. Inclusion/exclusion criteria {#sec0020}
---------------------------------

### 2.2.1. Inclusion criteria {#sec0025}

Studies were included if they reported human prospective intervention studies sampling adults (aged 18 years and over) with reported acute respiratory viral infection (ARVI).

### 2.2.2. Exclusion criteria {#sec0030}

Studies were excluded if the study sample was not reported as diagnosed with ARVI.

2.3. Databases {#sec0035}
--------------

Medline (Ovid), AMED (Ovid), CINAHL (EBSCO), EMBASE (Ovid)

2.4. Search terms (example) {#sec0040}
---------------------------

### 2.4.1. Medline (Ovid) {#sec0045}

**((** randomised Controlled Trials as Topic/ OR randomised controlled trial/ OR Random Allocation/ OR Double-Blind Method/ OR Single Blind Method/ OR clinical trial/ OR clinical trial, phase i.pt. OR clinical trial, phase ii.pt. OR clinical trial, phase iii.pt. OR clinical trial, phase iv.pt. OR controlled clinical trial.pt. OR randomised controlled trial.pt. OR multicenter study.pt. OR clinical trial.pt. OR exp Clinical Trials as topic/ OR (clinical adj trial\$).tw. OR ((singl\$ or doubl\$ or treb\$ or tripl\$) adj (blind\$3 or mask\$3)).tw. OR PLACEBOS/ OR placebo\$.tw. OR randomly allocated.tw. OR allocated adj2 random\$).tw.) NOT (letter/ OR historical article/)) AND ((Acetylcysteine or N-Acetyl-[l]{.smallcaps}-cysteine or N-Acetylcysteine or NAC or N-AC or N-acetyl).af.) AND (Influenza, Human/ OR Influenza A Virus, H1N1 Subtype/ OR Influenza A virus/ OR Influenza A Virus, H3N2 Subtype/ OR H1N1.mp. OR breathing OR lung OR pulmonary OR respir\$)

2.5. Critical appraisal {#sec0050}
-----------------------

The risk of bias (RoB) of study findings was assessed using the revised Cochrane RoB tool for randomised trials (RoB 2) <https://sites.google.com/site/riskofbiastool/welcome/rob-2-0-tool/current-version-of-rob-2?authuser=0>.

3. Results {#sec0055}
==========

The search identified 640 citations. Seven duplicates were removed leaving 633 citations to be screened. After title and abstract reviews, 91 citations were left with 76 citations further excluded as they didn't meet the inclusion and exclusion criteria \[wrong patient population = 48, wrong study design = 13, wrong intervention = 7, paediatric population = 6, wrong comparator = 1 and wrong outcome = 1\]. The remaining 13 articles were included in this rapid review. [Table 1](#tbl0005){ref-type="table"} show a summary of included studies.Table 1Summary of studies examining the effect of NAC in acute viral respiratory infections humans.Table 1AuthorCountryWHO Region (see WHO tab)Design (eg Cohort, cross-sectional)Study durationStudy Population / Disease or ConditionAdministration of NAC*DoseDuration of Treatment*Control or PlaceboTotal Number of SubjectsN in intervetion and placeboMeasure of OutcomeOutcomeBernard, et al. \[[@bib0015]\]USA, CanadaThe Region of the AmericasDBPC RCTMarch 17, 1992 to Feb 26, 1993ICU, diagnosed with ARDS and needing ventilationIV solution of 10 % NAC diluted with 5% dextrose in water70 mg (0.4 mol)/kg body weight; OTZ, 63 mg (0.4 mol)/kg of body weight30 min., every 8 h for a total of 30 doses during a 10-day treatment periodPlacebo (5%dextrose in water)n = 48NAC: n = 14 OTZ: n = 17 Placebo: n = 15RBC glutathione levelsNAC: increased from baseline 47 % (p \< .05)\
OTZ: not significant\
Placebo: not significantMortalityNo differenceOrgan-failure free daysNo differenceDomenighetti, et al. \[[@bib0020]\]SwitzerlandEuropeanPC RCT16-month periodICU patients diagnosed with ARDSIV solution190 mg/kg/day of NAC or placeboContinuous infusion over the first 3 daysPlacebo (saline)n = 42NAC: n = 22; Placebo: n = 20Incidence of ventilatory supportNo differencePaO~2~/FIO~2~No differenceLung Injury ScoreNAC: 1.53 (SD 0.21)\
Placebo: 2.15 (SD 0.19)\
(p \< .04)Chest radiographNo differenceHowe, et al. \[[@bib0025]\]America USAThe Region of the AmericasDBPC RCTICU patients requiring mechanical ventilationEnterally administered antioxidant supplementation via a bolusGroup 1: 5 mL dose of placebo; Group 2: 5 mL dose of vitamin E (100IU) and 5 mL dose of placebo; Group 3: rml dose of vitamin C (1000 mg), 5 mL dose of vitamin E (1000IU) and 5 mL dose of NAC (400 mg)Bolus given every 8 h for 28 days or until they were weaned from mechanical ventilation (whichever was shorter)Placebon = 72C + E+NAC: n = 23; Placebo: n = 22; C + E n = 27All-cause mortalityNo differenceDays in ICUNo differenceDays in hospitalNo differenceNumber of days on mechanical ventilationC + E group: Mean, 10 days\
C + E+NAC: Mean, 12 days\
Placebo: Mean, 19 days\
(p = .02)Jepsen, et al. \[[@bib0030]\]Denmark and SwedenEuropeanDBPC RCTICU patients diagnosed with ARDSIV solutionNAC 150 mg/kg as a loading dose and then 20 mg/kg/hrInitial dose was given for 30 min. on day one. Then continuous for the next 6 daysPlacebon = 66NAC: n = 32; Placebo: n = 34Adverse eventsNAC: a rash was observed in one patient after the loading dose.OxygenationNo differenceAdministration of corticosteriods, prostaglandin E~1~ or NSAIDsNo differenceTime taken to recover from ARDSNo differenceChest radiographsNo differenceLai, et al. \[[@bib0005]\]Hong KongSouth East AsiaCase reportNot applicableOne patient diagnosed with novel H1N1 influenza pneumonia, septic shock, type 1 respiratory failureIV solutionNAC 100 mg/kg continuous IV infusion for 3 days.Intial treatment with norepinephrine infusion, hdyrozortisone for septic shock. Oral oseltamivir 75 mg twice daily, IV antibiotics next day. Next day, oseltamivir 150 mg BD, IV NAC daily for 3 days.Nonen = 1n = 1Patient improved rapidly after high dose NAC therapy plus antiviral medications.\
CRP concentrations were also seen to decrease with the introduction of NAC high dose.Laurent, et al. \[[@bib0035]\]SwitzerlandEuropeanDB PC RCTICU patients diagnosed with severe ARDSIV solution190 mg/kg/day of NACContinuous infusion over the first 3 daysPlacebo (isotonic saline solution)n = 16NAC n = 8; Placebo n = 8Unstimulated oxygen radical productionNo differenceGranulocyte GSHSignificantly higher in the NAC group compared to placebo (p \< 0.01). Difference was abolished by day 5 (all treatment stopped on day 3).Elastase releaseNo differenceMoradi, et al. \[[@bib0040]\]IranEastern MediterraneanSB PC RCTJuly 2005 and April 2006Ventilated ICU patients with ALI/ARDSIV solution150 mg/kg at first day, followed by 50 mg/kg for 3 daysInitial dose was given for day one, then followed by continuous infusions for 3 daysPlacebo (5%dextrose in water)n = 30NAC: n = 14; Placebo: n = 13Mortality rateNAC: 35.7 %; Placebo: 76.9 % (p = .03)Duration of mechanical ventilationNo differenceLength of ICU stayNo differencePaO~2~/FiO~2~ (Day 2)NAC: 227.3 (SD 23.9); Placebo: 155.0 (SD 15.5) (p = .02)PaO~2~/FiO~2~ (Day 3)NAC: 344.0 (SD 38.3); Placebo: 166.5 (SD 119.0) (p \< .001)PaO~2~/FiO~2~ (Day 4)NAC: 440.9 (SD 47.5); Placebo: 151.2 (SD 24.6) (p \< .001)Ortolani, et al. \[[@bib0055]\]ItalyEuropeanRCTMay 1995 to October 1997ICU patients, diagnosed early ARDS requiring ventilationIV solution of 5% NAC diluted with 5% dextrose in water alone or combined with Rutin 0.5 %NAC 50 mg/kg OR NAC 50 mg/kg + Rutin 5 mg/kg every 8 h9 days (trial length) then as long as artificial ventilation was neededControl 250 mL 5% dextrose in watern = 36NAC: n = 12; NAC + Rutin: n = 12; Control: n = 12;Oxidised and total glutathione in epithelial lining fluid (ELF)No differenceOxygenationNAC: ImprovedLipid peroxidation (ethane expiration)\[Day 9\]\
NAC: reduced 43 %\
NAC + Rutin: reduced 46 %\
Placebo: reduced 15 % (p \< .01)Polymorphonuclear (PMN) cell count in ELFNAC: Reduced 50 %\
NAC + Rutin: Reduced 30 %\
Placebo: No change\
(p \< .05)Mortality \[day 9 and day 30\]No differenceSharafkhah, et al. \[[@bib0045]\]IranEastern MediterraneanDBPC RDTMarch 2014 to June 2016Adult ICU admitted patients undergoing endotracheal intu-bation and mechanical ventilationNAC (600 mg; water-soluble tablets) through nasogastric tubeTwice dailyAdministered within the first 12 h of mechanical ventilation after hospital admission, and continued until performing extubation, tracheostomy, discharge, or death.Placebo (water-soluble vitamin tablets)n = 60NAC: n = 30; Placebo: n = 30Incidence of ventilator-associated pneumoniaNAC: 26.6 %\
Placebo: 46.6 %\
(p = .032)Time to recoveryPatients who survived in the treatment group showed a more rapid recovery compared with the control group.Incidence of ventilator associated pneumonia (VAP)Patients treated with NAC were significantly less likely to develop clinically confirmed VAP compared with patients treated with placebo.Time to VAP (days)NAC: 6.42 (SD 1.9)\
Placebo: 3.46 (SD 2.53)\
(p = .002)Duration of mechanical ventilation (days)No differenceICU stay (days)NAC: 14.36 (SD 4.69)\
Placebo: 17.81 (SD 6.37)\
(p = .028)Hospital stay (days)NAC: 19.23 (SD 5.54\
Placebo: 24.61 (SD 6.81)\
(p = .030)Recovery rate of VAP*Complete -* NAC: 56.6%; Placebo: 30% (p = .006)\
*Modest* -- no difference\
*Lack* -- NAC: 10.0%; Placebo: 26.6% (p = .040)\
*Death*: no differenceAdverse eventsNo adverse events related to NAC were identified.Soltan-Sharifi, et al. \[[@bib0010]\]IranEastern MediterraneanControlled clinical trial24 July 2005 and 30 April 2006ICU patients with Illness known to be associated with ALI/ARDS who required mechanical ventilation\"Infused\" NAC (150 mg/kg) diluted in 5% dextrose and and 50 mg/kg/day diluted in 5% dextroseNAC (150 mg/kg) infused for 20 min the first day and then 50 mg/kg/day for three days.3 daysNonen = 24NAC: n = 14; Control: n = 10Acute Physiology and Chronic Health Evaluation(APACHE II) scoreNAC: Increased\
Placebo: Decreased\
(p \< .01)Intracellular glutathione (GSH) (48 h)NAC: Increased 59 %\
Placebo: Decreased 23 %\
(p \< .001)GSH/GSSG ratioNAC: Increased (22 vs 64.2)\
Placebo: No change\
(p \< .01)Total antioxidant power (TAP) (mmol/L) (72 h)NAC: 3.6 (SD 0.38)\
Placebo: 1.8 (SD 0.25)\
(p = .013)Suter, et al. \[[@bib0050]\]SwitzerlandEuropeanDBPC RDT12- month periodPatients with risk factors for ARDS, and presenting with mild-to-moderate acute lung injuryContinuous IV infusionNAC 40 mg/kg/day3 daysPlacebon = 61NAC: n = 32; Placebo: n = 29Incidence of ventilatory supportNAC: Reduced (69 % vs 17 %)\
Placebo: Reduced (76 % vs 48 %)\
(p = .01)FiO~2~ administeredNAC: Reduced (0.29 vs 0.48)\
Placebo: No difference (0.35 vs 0.48)\
(p \< .05)PaO~2~/FiO~2~No differenceLung injury scoreNAC: Decreased (1.39 vs 0.67)\
Placebo: No difference\
(p \< .01)Chest radiograph scoreNAC: No change at day 3; Decreased at discharge (1.8 vs 1.1)\
Placebo: Increased at day 3\
(p \< .05)van Meenen, et al. \[[@bib0060]\]NetherlandsEuropeanRCTJune 22, 2014, to November 24, 2016ICU patients receiving invasive ventilationNebulized 5 mL solution (300 mg acetylcysteine) administered alone or in combination with 5 mL solutions containing salbutamol (2.5 mg)On demand nebulization group: 5 ml solutions containing acetylcysteine (300 mg) OR 5 ml solutions containing salbutamol (2.5 mg) dependent on patient presentation. Routine nebulization group: acetylcysteine (300 mg) with salbutamol (2.5 mg) four times dailyMaximum 28 days. On demand group were reassessed daily. Routine group - from start to end of invasive ventilation and, in the case of ventilation through a tracheostomy tube, until ventilator support was discontinued for longer than 24 h.Nonen = 842On-demand group: n = 389; Routine group: n = 453Number of ventilator-free daysNo differenceMortalityNo differenceICU and hospital length of stayNo differenceAdverse events*Total*\
On demand: 13.8 %\
Routine: 29.3 %\
(p \< .001)\
*Tachyarrhythmia*\
On demand:\
12.5 %\
Routine: 25.9 % (p \< .001)\
*Agitation*\
On demand: 0.2 %\
Routine: 4.3 %\
(p \< .001)Zhang, et al. \[[@bib0065]\]ChinaWestern Pacific RegionRCTAugust 2016 and March 2017All patients admitted to the hospital with community acquired pneumoniaOral 600 mg tabletNAC 1200 mg (600 mg tablet twice daily)10 daysStandard caren = 39NAC: n = 21; Standard care: n = 18Malondialdehyde (7 days)NAC: +1.34 (SD 1.35)\
Non-NAC: +0.43 (SD 1.28)\
(p = .004)Tumour-necrosis factor-αNAC: +9.5 (SD 3.62)\
Non-NAC: 6.25 (SD 3.98)\
(p \< .001)Total antioxidant capacityNAC: +4.16 (SD 2.95)\
Non-NAC: +1.78 (SD 3.21)\
(p = .005)Superoxide dismutaseNo differenceCT Image comparisonNo difference

All but two studies were identified as randomised controlled trials (RCTs). The two non-RCTs comprised of a case report \[[@bib0005]\] and a controlled clinical trial \[[@bib0010]\]. Eight of the 13 (61.5 %) included trials were placebo-controlled \[[@bib0015], [@bib0020], [@bib0025], [@bib0030], [@bib0035], [@bib0040], [@bib0045], [@bib0050]\], and 6/13 (46.1 %) were double-blinded \[[@bib0015],[@bib0025], [@bib0030], [@bib0035],[@bib0045],[@bib0050]\].

Studies were conducted across five of six World Health Organisation (WHO) regions, with most undertaken in the European region (6/13 \[46.2 %\] \[[@bib0020],[@bib0030],[@bib0035],[@bib0050], [@bib0055], [@bib0060]\]), followed by the Eastern Mediterranean (3/13 \[23.0 %\] \[[@bib0010],[@bib0040],[@bib0045]\];), Americas (2/13 \[15.4 %\] \[[@bib0015],[@bib0025]\];), South East Asia (1/13 \[7.7 %\] \[[@bib0005]\];) and Western Pacific (1/13 \[7.7 %\] \[[@bib0065]\];) regions. All studies were conducted in a hospital setting, and all but two \[[@bib0005],[@bib0065]\] were reportedly undertaken in an intensive care unit.

The 13 included studies comprised a total pool of 1337 subjects, with study sample sizes ranging from 1 to 842 (median 42). All subjects had an acute respiratory condition, with diagnoses including ALI/ARDS (7/13 \[53.9 %\]; \[[@bib0010], [@bib0015], [@bib0020],[@bib0030], [@bib0035], [@bib0040],[@bib0050]\]) or pneumonia (2/13 \[15.4 %\] \[[@bib0005],[@bib0065]\];). Four studies (30.8 %) did not define the respiratory disorder \[[@bib0025],[@bib0045],[@bib0055],[@bib0060]\].

N-Acetyl Cysteine (NAC) was predominantly administered intravenously (10/13 \[76.9 %\]; 40−480 mg/kg/day or 400 mg TDS via intravenous infusion; \[[@bib0005], [@bib0010], [@bib0015], [@bib0020], [@bib0025], [@bib0030], [@bib0035], [@bib0040],[@bib0050],[@bib0055]\]), and to a lesser extent, as an oral tablet (2/13 \[15.4 %\]; 600 mg BD \[[@bib0045],[@bib0065]\];) or via nebuliser (1/13 \[7.7 %\]; 300 mg QID or on demand \[[@bib0060]\];). Control interventions included 5% dextrose in water (3/13 \[23.1 %\] \[[@bib0015],[@bib0040],[@bib0055]\];), saline (2/13 \[15.4 %\] \[[@bib0020],[@bib0035]\];), water-soluble vitamin tablets (1/13 \[7.7 %\] \[[@bib0045]\];), conventional treatment only (1/13 \[7.7 %\] \[[@bib0065]\];), and non-specified placebo (3/13 \[23.1 %\] \[[@bib0025],[@bib0030],[@bib0050]\];). The duration of treatment ranged from 3 to 28 days, with a median period of 3 days.

4. Critical appraisal {#sec0060}
=====================

In the first Domain (randomisation process), two studies were rated as high risk of bias \[[@bib0005],[@bib0020]\] with all other studies rated as low. For Domain 2 (treatment assignment), one trial was identified as high risk of bias \[[@bib0030]\], with seven trials rated as low \[[@bib0010], [@bib0015], [@bib0020], [@bib0025],[@bib0045],[@bib0060]\]. Under Domain 3 (missing outcome data), two trials were considered to have high risk of bias \[[@bib0030],[@bib0035]\], with eight trials rated as low \[[@bib0015],[@bib0015],[@bib0020],[@bib0025],[@bib0040],[@bib0050],[@bib0060],[@bib0065]\]. For Domain 4 (measure of outcomes), all trials were rated as low risk of bias, except Lai et al. \[[@bib0005]\], which was assessed as having some concerns. In Domain 5 (selective reporting), one trial \[[@bib0055]\] was identified as high risk of bias, with the remaining trials rated as having some concerns or low risk of bias. Overall, five studies were judged as having high risk of bias \[[@bib0005],[@bib0020],[@bib0030],[@bib0035],[@bib0055]\], six rated as having some concerns \[[@bib0010],[@bib0025],[@bib0040], [@bib0045], [@bib0050],[@bib0065]\] and two judged as low risk of bias \[[@bib0015],[@bib0060]\]. These judgements should be taken into consideration when interpreting the findings of this review.

5. Summary of findings {#sec0065}
======================

The 13 included studies reported on nine broad outcomes: markers of inflammation and oxidation, changes in CT or x-ray images, patient length of stay, mortality rate, pulmonary complications, ventilation-related issues, recovery rate, clinical improvement and adverse events.

Four RCTs \[[@bib0015],[@bib0035],[@bib0055],[@bib0065]\] reported changes in markers of inflammation or oxidation. These studies reported significant improvements in GSH, tumour necrosis factor - α (TNF-α), malondialdehyde, total thioles, lipoperoxidation, total antioxidant power and polymorphonuclear cell activity following NAC administration when compared to controls. These findings were consistent with those reported in the two non-RCTs \[[@bib0005],[@bib0010]\]). No differences between groups were reported for superoxide dismutase and elastase.

Changes in CT or x-ray images were measured in two RCTs \[[@bib0030],[@bib0065]\]. Both studies found no differences in this outcome between NAC and control.

Three RCTs \[[@bib0025],[@bib0045],[@bib0060]\] assessed patient length of stay. Although one RCT \[[@bib0045]\] reported a significant reduction in ICU and hospital length of stay in the NAC group versus control, two studies \[[@bib0025],[@bib0060]\] found no differences between groups in patient length of stay.

Mortality rate was measured in six RCTs \[[@bib0015], [@bib0020], [@bib0025],[@bib0040],[@bib0050],[@bib0060]\]. Four studies \[[@bib0015],[@bib0025],[@bib0050],[@bib0060]\] reported no differences in mortality rates between NAC and control. The remaining studies reported conflicting results, with one RCT \[[@bib0040]\] revealing a reduction in the rate of mortality following NAC administration (relative to control), and the other RCT \[[@bib0020]\] reporting an increase in mortality rate with NAC administration.

Three RCTs \[[@bib0045],[@bib0050],[@bib0060]\] examined the efficacy of NAC in preventing pulmonary complications. When compared to control, NAC administration was associated with a significant reduction in ventilator-associated pneumonia and time to ventilator-associated pneumonia in 1 RCT \[[@bib0045]\]. However, in two RCTs \[[@bib0050],[@bib0060]\], no difference was found between groups in the prevalence of pulmonary complications.

Ventilation-related issues were reported as an outcome in four RCTs \[[@bib0020],[@bib0025],[@bib0040],[@bib0050]\]. NAC administration was associated with improvements in systemic oxygenation in two \[[@bib0040],[@bib0050]\] of 3 RCTs, and a reduction in the need for / duration of ventilation in two \[[@bib0025],[@bib0050]\] of three RCTs.

Four RCTs \[[@bib0015],[@bib0030],[@bib0045],[@bib0055]\] and one case report \[[@bib0005]\] examined recovery rate following NAC administration. All but one study \[[@bib0030]\] reported a significant improvement in the rate of recovery from an acute respiratory condition with NAC administration when compared with control.

Clinical improvement was assessed in one controlled clinical trial \[[@bib0010]\]. The authors indicated that NAC administration was associated with an improvement in Acute Physiology and Chronic Health Evaluation (APACHE II) score -- a measure of clinical improvement and a predictor of mortality risk.

Adverse event monitoring was reported in three RCTs \[[@bib0030],[@bib0045],[@bib0065]\]. Two studies \[[@bib0045],[@bib0065]\] reported no adverse events with NAC administration, and 1 \[[@bib0030]\] reported a rash during the administration of a loading dose of NAC.

6. Clinical significance {#sec0070}
========================

From the evidence identified in this review, it is recommended that NAC could be used for people who have contracted Covid-19. At early stages of the disease, health practitioners could recommend oral NAC \[600 mg BD\] to assist in reducing respiratory mucus and inflammation, increasing systemic GSH levels and possibly averting hospital admission. As only three trials assessed the oral administration of NAC, and there were some concerns with the risk of bias of these studies, these suggestions need to be considered with caution until conclusive evidence becomes available. If health professionals have access and ability to administer NAC via nebuliser or IV, the review findings suggest that doses of NAC ranging from 40−480 mg/kg/day for at least 3 days may be suitable for patients who are deteriorating. Again, as two of the ten studies on IV administration of NAC were rated as high risk of bias, patients who are administered NAC intravenously need to be monitored closely.

Health practitioners are advised that these recommendations should complement, and not replace, standard medical care, and if required, the patient is recommended to obtain emergency care where needed.

Disclaimer {#sec0075}
==========

This article should not replace individual clinical judgement. The views expressed in this rapid review are the views of the authors and not necessarily from the host institutions. The views are not a substitute for professional medical advice.

Appendix A. Supplementary data {#sec0085}
==============================

The following are Supplementary data to this article:

Supplementary data associated with this article can be found, in the online version, at <https://doi.org/10.1016/j.aimed.2020.07.006>.
